Lasp1 is down-regulated in NMDA receptor antagonist-treated mice and implicated in human schizophrenia susceptibility

Journal of Psychiatric Research

Volumn 47, Issue 1, 2013, Pages 105-112

  Joo, Jaesoon ^a   Lee, Soojeong ^a   Nah, Seong Su ^a   Kim, Young Ock ^b   Kim, Duk Soo ^a   Shim, Se Hoon ^a   Hwangbo, Young ^a   Kim, Hyung Kee ^a   Kwon, Jun Tack ^a   Kim, Jong Woo ^c   Song, Ho Yeon ^a   Kim, Hak Jae ^a  

^a Soonchunhyang University   (South Korea)

^b Rural Development Administration   (South Korea)

^c Kyung Hee University Hospital   (South Korea)

Author keywords

Lasp1; MK 801; Schizophrenia; Two dimensional electrophoresis

Indexed keywords

ACTIN; DIZOCILPINE; LASP1 PROTEIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PROTEIN; PROTEOME; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOSKELETON; DISEASE PREDISPOSITION; DOWN REGULATION; GENETIC POLYMORPHISM; HIPPOCAMPUS; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOLECULE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; TWO DIMENSIONAL ELECTROPHORESIS; WESTERN BLOTTING;

EID: 84869882202     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2012.09.005     Document Type: Article

References (45)

1. American Psychiatric Association Diagnostic and statistical manual of mental disorders 1994, American Psychiatric Press, Washington, DC. 4th ed.
2. Blennow K., Davidsson P., Gottfries C.G., Ekman R., Heilig M. Synaptic degeneration in thalamus in schizophrenia. Lancet 1996, 348:692-693.
3. Carlsson M., Carlsson A. Interactions between glutamatergic and monoaminergic systems within the basal ganglia - implications for schizophrenia and Parkinson's disease. Trends in Neurosciences 1990, 13:272-276.
4. Chew C.S., Chen X., Parente J.A., Tarrer S., Okamoto C., Qin H.Y. Lasp-1 binds to non-muscle F-actin in vitro and is localized within multiple sites of dynamic actin assembly in vivo. Journal of Cell Science 2002, 115:4787-4799.
5. Chew C.S., Parente J.A., Zhou C., Baranco E., Chen X. Lasp-1 is a regulated phosphoprotein within the cAMP signaling pathway in the gastric parietal cell. American Journal of Physiology 1998, 275:C56-C67.
6. Clineschmidt B.V., Martin G.E., Bunting P.R., Papp N.L. Central sympathomimetic activity of (+)-5-methyl-10,11-dihydro-5H-dibenzo [d] cyclohepten-5, 10-immine(MK-801), a substance with potent anticonvulsant, central sympathomimetic, and apparent anxiolytic properties. Drug Development Research 1982, 2:135-145.
7. Clinton S.M., Meador-Woodruff J.H. Thalamic dysfunction in schizophrenia: neurochemical, neuropathological, and in vivo imaging abnormalities. Schizophrenia Research 2004, 69:237-253.
8. Davidsson P., Gottfries J., Bogdanovic N., Ekman R., Karlsson I., Gottfries C.G., et al. The synaptic-vesicle-specific proteins rab3a and synaptophysin are reduced in thalamus and related cortical brain regions in schizophrenic brains. Schizophrenia Research 1999, 40:23-29.
9. DeLisi L.E., Sakuma M., Tew W., Kushner M., Hoff A.L., Grimson R. Schizophrenia as a chronic active brain process: a study of progressive brain structural change subsequent to the onset of schizophrenia. Psychiatry Research 1997, 74:129-140.
10. Deutsch S.I., Rosse R.B., Mastropaolo J. Behavioral approaches to the functional assessment of NMDA-mediated neural transmission in intact mice. Clinical Neuropharmacology 1997, 20:375-384.
11. Eastwood S.L., Burnet P.W., Harrison P.J. Altered synaptophysin expression as a marker of synaptic pathology in schizophrenia. Neuroscience 1995, 66:309-319.
12. Eastwood S.L. The synaptic pathology of schizophrenia: is aberrant neurodevelopment and plasticity to blame?. International Review of Neurobiology 2004, 59:47-72.
13. Ellison G. The N-methyl-d-aspartate antagonists phencyclidine, ketamine and dizocilpine as both behavioral and anatomical models of the dementias. Brain Research Reviews 1995, 20:250-267.
14. Eyjolfsson E.M., Brenner E., Kondziella D., Sonnewald U. Repeated injection of MK801: an animal model of schizophrenia?. Neurochemistry International 2006, 48:541-546.
15. Fornito A., Yücel M., Pantelis C. Reconciling neuroimaging and neuropathological findings in schizophrenia and bipolar disorder. Current Opinion in Psychiatry 2009, 22:312-319.
16. Gabriel S.B., Schaffner S.F., Nguyen H., Moore J.M., Roy J., Blumenstiel B., et al. The structure of haplotype blocks in the human genome. Science 2002, 296:2225-2229.
17. Grunewald T.G., Butt E. The LIM and SH3 domain protein family: structural proteins or signal transducers or both?. Molecular Cancer 2008, 7:31.
18. Harrison P.J. The hippocampus in schizophrenia: a review of the neuropathological evidence and its pathophysiological implications. Psychopharmacology (Berl) 2004, 174:151-162.
19. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. The American Journal of Psychiatry 1991, 148:1301-1308.
20. Jentsch J.D., Roth R.H. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1999, 20:201-225.
21. Kim H.J., Kim M.H., Choe B.K., Kim J.W., Park J.K., Cho A.R., et al. Genetic association between 5'-upstream single-nucleotide polymorphisms of PDGFRB and schizophrenia in a Korean population. Schizophrenia Research 2008, 103:201-208.
22. Kotecha S.A., Oak J.N., Jackson M.F., Perez Y., Orser B.A., Van Tol H.H., et al. A D2 class dopamine receptor transactivates a receptor tyrosine kinase to inhibit NMDA receptor transmission. Neuron 2002, 35:1111-1122.
23. Lawrie S.M., Whalley H., Kestelman J.N., Abukmeil S.S., Byrne M., Hodges A., et al. Magnetic resonance imaging of brain in people at high risk of developing schizophrenia. Lancet 1999, 353:30-33.
24. Lee S.K., Kang S.W., Kim S.K., Kim H.J., Kim T., Park J.K., et al. Association analysis between polymorphisms of NOTCH4 gene and schizophrenia in Korean population. Molecular and Cellular Toxicology 2009, 5:160-164.
25. Li K., Hornshaw M.P., van Minnen J., Smalla K.H., Gundelfinger E.D., Smit A.B. Organelle proteomics of rat synaptic proteins: correlation-profiling by isotope-coded affinity tagging in conjunction with liquid chromatography-tandem mass spectrometry to reveal post-synaptic density specific proteins. Journal of Proteome Research 2005, 4:725-733.
26. Lin Y.H., Park Z.Y., Lin D., Brahmbhatt A.A., Rio M.C., Yates J.R., et al. Regulation of cell migration and survival by focal adhesion targeting of Lasp-1. Journal of Cell Biology 2004, 165:421-432.
27. Oak J.N., Lavine N., Van Tol H.H. Dopamine D(4) and D(2L) receptor stimulation of the mitogen-activated protein kinase pathway is dependent on trans-activation of the platelet-derived growth factor receptor. Molecular Pharmacology 2001, 60:92-103.
28. Park H.J., Rajbhandari I., Yang H.S., Lee S., Cucoranu D., Cooper D.S., et al. Neuronal expression of sodium/bicarbonate cotransporter NBCn1 (SLC4A7) and its response to chronic metabolic acidosis. American Journal of Physiology - Cell Physiology 2010, 298:C1018-C1028.
29. Paulson L., Martin P., Nilsson C.L., Ljung E., Westman-Brinkmalm A., Blennow K., et al. Comparative proteome analysis of thalamus in MK-801-treated rats. Proteomics 2004, 4:819-825.
30. Paulson L., Martin P., Persson A., Nilsson C.L., Ljung E., Westman-Brinkmalm A., et al. Comparative genome- and proteome analysis of cerebral cortex from MK-801-treated rats. Journal of Neuroscience Research 2003, 71:526-533.
31. Phillips G.R., Anderson T.R., Florens L., Gudas C., Magda G., Yates J.R., et al. Actin-binding proteins in a postsynaptic preparation: lasp-1 is a component of central nervous system synapses and dendritic spines. Journal of Neuroscience Research 2004, 78:38-48.
32. Qi C., Zou H., Zhang R., Zhao G., Jin M., Yu L. Age-related differential sensitivity to MK-801-induced locomotion and stereotypy in C57BL/6 mice. European Journal of Pharmacology 2008, 580:161-168.
33. Ross C.A., Margolis R.L., Reading S.A., Pletnikov M., Coyle J.T. Neurobiology of schizophrenia. Neuron 2006, 52:139-153.
34. Sokolov B.P., Tcherepanov A.A., Haroutunian V., Davis K.L. Levels of mRNAs encoding synaptic vesicle and synaptic plasma membrane proteins in the temporal cortex of elderly schizophrenic patients. Biological Psychiatry 2000, 48:184-196.
35. Sommer S., Hunzinger C., Schillo S., Klemm M., Biefang-Arndt K., Schwall G., et al. Molecular analysis of homocysteic acid-induced neuronal stress. Journal of Proteome Research 2004, 3:572-581.
36. Stone J.L., Merriman B., Cantor R.M., Geschwind D.H., Nelson S.F. High density SNP association study of a major autism linkage region on chromosome 17. Human Molecular Genetics 2007, 16:704-715.
37. Tamminga C.A., Holcomb H.H. Phenotype of schizophrenia: a review and formulation. Molecular Psychiatry 2005, 10:27-39.
38. Tamminga C.A., Holcomb H.H., Gao X.M., Lahti A.C. Glutamate pharmacology and the treatment of schizophrenia: current status and future directions. International Clinical Psychopharmacology 1995, 3:29-37.
39. Terasaki A.G., Suzuki H., Nishioka T., Matsuzawa E., Katsuki M., Nakagawa H., et al. A novel LIM and SH3 protein (lasp-2) highly expressing in chicken brain. Biochemical and Biophysical Research Communications 2004, 313:48-54.
40. Tomasetto C., Moog-Lutz C., Régnier C.H., Schreiber V., Basset P., Rio M.C. Lasp-1 (MLN 50) defines a new LIM protein subfamily characterized by the association of LIM and SH3 domains. FEBS Letters 1995, 373:245-249.
41. Velakoulis D., Wood S.J., Wong M.T., McGorry P.D., Yung A., Phillips L., et al. Hippocampal and amygdala volumes according to psychosis stage and diagnosis: a magnetic resonance imaging study of chronic schizophrenia, first-episode psychosis, and ultra-high-risk individuals. Archives of General Psychiatry 2006, 63:139-149.
42. Wright I.C., Rabe-Hesketh S., Woodruff P.W., David A.S., Murray R.M., Bullmore E.T. Meta-analysis of regional brain volumes in schizophrenia. American Journal of Psychiatry 2000, 157:16-25.
43. Wu J., Zou H., Strong J.A., Yu J., Zhou X., Xie Q., et al. Bimodal effects of MK-801 on locomotion and stereotypy in C57BL/6 mice. Psychopharmacology (Berl) 2005, 177:256-263.
44. Zieseniss A., Terasaki A.G., Gregorio C.C. Lasp-2 expression, localization, and ligand interactions: a new Z-disc scaffolding protein. Cell Motility and the Cytoskeleton 2008, 65:59-72.
45. Zuo D.Y., Zhang Y.H., Cao Y., Wu C.F., Tanaka M., Wu Y.L. Effect of acute and chronic MK-801 administration on extracellular glutamate and ascorbic acid release in the prefrontal cortex of freely moving mice on line with open-field behavior. Life Sciences 2006, 78:2172-2178.